Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis
Reproductive Sciences · 2025-05 · 32 (5) · 1661-1675
DOI: 10.1007/s43032-025-01788-9 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Reproductive Sciences, online erschienen am 29.01.2025. Verfasst von Yuzi Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430064, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Metformin, Polycystic Ovary Syndrome. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
This study compared the efficacy and safety of glucogan-like peptide-1 receptor agonists (GLP1RAs) combined with metformin versus metformin alone in women with polycystic ovary syndrome (PCOS). A systematic search of "PubMed", "EMBASE", "Cochrane Library", and "Web of Science", "Google Scholar" was conducted up to September 2024. Studies were included if they were RCTs investigating the combination of GLP1RAs and metformin in women diagnosed with PCOS. Eligible studies compared this combination therapy to metformin alone. Primary outcomes included changes in body weight, BMI, waist circumference, fasting glucose, HOMA-IR, androgen levels, and sex hormone-binding globulin (SHBG). Meta-analysis was performed using RevMan 5.4 software. Eight RCTs with a total of 337 participants were included. The combination of GLP1RAs and metformin resulted in significant reductions in body weight (mean difference [MD]=-1.37 kg, 95% CI [-2.07, -0.67]; P = 0.0001), BMI (MD= -0.88 kg/m², 95% CI [-1.37, -0.39]; P = 0.0005), waist circumference (MD= -2.46 cm, 95% CI [-3.59,-1.33]; P < 0.0001), fasting glucose level (MD= -0.30, 95% CI [-0.42,-0.17]; P < 0.0001), and glucose level at 2 h after OGTT (MD= -1.58, 95% CI [-2.10,-1.06]; P < 0.0001) compared to metformin alone. Improvements in insulin sensitivity (HOMA-IR) in GLP1RA + Met group were also observed (MD=-1.58, 95% CI [-2.10, -1.06]; P < 0.0001) comparing to Met group. Hormonal outcomes demonstrated an increase in SHBG (MD = 10.04, 95% CI [7.06, 13.01]; P < 0.0001). Adverse events were not different between GLP1RA + Met and Met groups. Collectivley, combination of GLP1RAs and metformin provides superior benefits over metformin alone in reducing body weight, improving insulin sensitivity, and regulating hormonal imbalances in women with PCOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430064, China.
- Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430064, China. jiangli_whu@outlook.com.
- Jiayu County Maternal and Child Health Hospital, Jiayu, China.
- Wuhan Caidian District Maternal and Child Health Hospital of Wuhan, Wuhan, China.
ORCID-Profile: Li Jiang
Zitieren
APA
Zhao, Y., Jiang, L., Li, N., Cao, J., & Pi, J. (2025). Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis. Reproductive Sciences, 32(5), 1661-1675. https://doi.org/10.1007/s43032-025-01788-9
Vancouver
Zhao Y, Jiang L, Li N, Cao J, Pi J. Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis. Reproductive Sciences. 2025;32(5):1661-1675. doi:10.1007/s43032-025-01788-9
BibTeX
@article{Zhao2025,
author = {Zhao, Yuzi and Jiang, Li and Li, Na and Cao, Jing and Pi, Jie},
title = {Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis},
journal = {Reproductive Sciences},
year = {2025},
volume = {32},
number = {5},
pages = {1661--1675},
doi = {10.1007/s43032-025-01788-9}
}
EUVIMED